Experimental vaccine aims to stop liver cancer from returning

NCT ID NCT06218511

Ongoing Disease control Sponsor: National Cancer Institute, Naples Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a cancer vaccine (IMA970A) combined with an immunotherapy drug (durvalumab) in 10 patients with early- to intermediate-stage liver cancer who have already received standard treatments. The goal is to see if the combination is safe and can help reduce the risk of the cancer coming back. Participants will receive the vaccine and drug without other anti-cancer therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a peptide vaccine (IMA970A) combined with an immune checkpoint inhibitor (durvalumab) and an adjuvant (Montanide)
What this could lead to: If successful, this could point toward a new way to lower the chance of liver cancer coming back after standard treatments.
What could go wrong: This is a very early, small phase I trial with only 10 participants, so it is mainly testing safety. The vaccine may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Luigi Buonaguro

Naples, Napoli, 80131, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.